Abstract

Guzal Abdullaeva, Gulnoz Khamidullaeva, Ravshanbek Kurbanov, Anvar Karimov, Nigora Tursunova, Prof. Alisher Abdullaev*, Shukhrat Masharipov and Malohat Akhmedova

ABSTRACT

Objective: The present study aimed to evaluate pharmacogenetic aspects of the antihypertensive, cardioprotective efficacy and clinical safety of 12-week Zofenopril monotherapy in association with the CYP11B2 C-344T polymorphism in Uzbek hypertensive patients. Materials and Methods: In order to study prevalence of CYP11B2 C-344T polymorphism there were selected 150 Uzbek hypertensive patients with Stage I-III of arterial hypertension (ESH/ESC, 2013), as well as 58 healthy Uzbeks aged from 30 to 70 years. The clinical efficacy of 12-week Zofenopril monotherapy in association with the CYP11B2 C-344T polymorphism was studied in 39 Uzbek hypertensive patients with Stage I-II of AH (ESH/ESC, 2013) (mean age 44.5±9.9 years, mean duration of AH was 4.3 ±4.4 years). Results: The prevalence of CT-heterozygotes and T-allele of the CYP11B2 C-344T polymorphism in Uzbek hypertensive patients was determined. The analysis in the subgroups with various carriers of CYP11B2 C-344T polymorphism revealed advances of the antihypertensive and cardioprotective efficacy of Zofenopril monotherapy in patients-carriers of TC+CC genotypes in comparison with carriers of TT-genotypes. The intensity of LVH and LVDD was associated with carrying of TT-genotype of CYP11B2 gene. Conclusion: The advanced antihypertensive and cardioprotective effect of Zofenopril monotherapy in hypertensive patients is associated with TC+CC genotypes.